Semaglutide: Beginning a New Era The first generation of GLP-1 receptor agonists achieved less than 10 percent weight loss on average
Dental and medical workers may contract herpetic whitlow by touching the contagious lesions of a patient with HSV infection
Dermatology (Basel, Switzerland)
no consistent signal for organ toxicity or long-term harm across decades of use Special Populations: Clinical experience exists in elderly patients with dementia and stroke patients, populations where safety data is particularly valuable IV Administration Considerations: Requires clinical administration setting for intravenous dosing, which limits convenience but ensures medical oversight Dihexa: Unknown Human Safety Profile Dihexa has never been administered to humans in any controlled setting, creating a complete absence of human safety data: No Human Pharmacokinetics: Absorption, distribution, metabolism, and excretion parameters are unknown in humans Theoretical c-Met Oncogenesis Concern: The c-Met/HGF pathway is implicated in cancer progression aberrant c-Met signaling promotes tumor growth, metastasis, and angiogenesis in multiple cancer types
There is IV therapy for patients that want to improve muscle mass, or support the immune system, or NAD for cell regeneration, which is the best anti-aging solution on the market, Mrs
Andersen JV (2025) The glutamate/GABAglutamine cycle: insights, updates, and advances
